Edition:
India

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.22USD
21 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.22
Open
$4.22
Day's High
$4.29
Day's Low
$4.18
Volume
114,840
Avg. Vol
289,694
52-wk High
$9.85
52-wk Low
$3.77

Latest Key Developments (Source: Significant Developments)

Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS.INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION.INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO'S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY.  Full Article

Inovio Receives Milestone Payment From Medimmune
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2.  Full Article

Inovio Announces Analysis Of VGX-3100 Phase 2b Data
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO’S FURTHER ANALYSIS OF VGX-3100 PHASE 2B DATA REVEALS IMMUNE CORRELATES AND BIOMARKER SIGNATURES THAT PREDICTED CLINICAL EFFICACY.INOVIO PHARMACEUTICALS - ‍IN 2018, CO TO INITIATE PHASE 2 "PROOF-OF-CONCEPT" STUDY FOR TREATMENT OF HIGH GRADE ANAL NEOPLASIA.  Full Article

Inovio pharmaceuticals reports 2017 third quarter financial results
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals reports 2017 third quarter financial results.Q3 loss per share $0.39.Q3 revenue $2.6 million versus $12.5 million.Q3 revenue view $9.4 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Inovio Pharmaceuticals - ‍as of Sept 30, 2017, cash and cash equivalents and short-term investments were $141.9 million versus $104.8 million as of Dec 31, 2016​.  Full Article

Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14.Inovio Pharmaceuticals - Approval ‍included amendment to the $35 million payment co to receive from Apollobio as per agreement agreed between co, Apollobio.Inovio Pharmaceuticals says amendment was to reduce the purchase price of the $35 million payment from $8.20 to $7.22 per share - SEC Filing​.  Full Article

Inovio Pharmaceuticals qtrly loss per share $0.35
Thursday, 16 Mar 2017 

Inovio Pharmaceuticals Inc : Inovio pharmaceuticals reports 2016 fourth quarter and year end financial results . Q4 revenue $8.5 million . Qtrly loss per share $0.35 .Q4 revenue view $5.9 million -- Thomson Reuters I/B/E/S.  Full Article

Inovio, Apollobio to develop and commercialize hpv pre-cancer immunotherapy VGX-3100 in Greater China
Monday, 13 Feb 2017 

Inovio Pharmaceuticals Inc : Inovio and Apollobio to collaborate on development and commercialization of hpv pre-cancer immunotherapy VGX-3100 in Greater China . Inovio Pharmaceuticals Inc - Inovio will receive $15 million in upfront and near term payments comprising an initial $3 million signing fee . Inovio Pharmaceuticals Inc - Inovio will receive a $12 million milestone upon lifting of VGX-3100 Phase 3 pre-initiation clinical hold by FDA . Inovio Pharmaceuticals Inc - under a separate equity agreement, Apollobio will invest in Inovio common stock subsequent to lifting of clinical hold . Inovio Pharmaceuticals Inc - aggregate investment, which is expected to be completed in first half of 2017, will not exceed $35 million . Inovio Pharmaceuticals Inc - Apollobio will fund all clinical development costs within licensed territory, and will pay Inovio up to $20 million . Inovio Pharma- agreements are subject to People's Republic of China corporate and regulatory approvals, payments are subject to PRC currency approvals .Inovio - payment of $20 million based upon achievement of certain regulatory milestones in U.S., China, Korea, double digit royalties on net sales of VGX-3100.  Full Article

Inovio launches Zika vaccine trial
Monday, 29 Aug 2016 

Inovio Pharmaceuticals Inc : Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy . Expects to report results before end of this year .Is developing its Zika vaccine, GLS-5700, with Geneone Life Science, Inc. And academic collaborators from US and Canada.  Full Article

Inovio Pharmaceuticals Q2 loss per share $0.26
Monday, 8 Aug 2016 

Inovio Pharmaceuticals Inc : Inovio Pharmaceuticals reports 2016 second quarter financial results . Q2 revenue $6.2 million versus $5.3 million . Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.26 .Q2 revenue view $5 million -- Thomson Reuters I/B/E/S.  Full Article

Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial
Tuesday, 26 Jul 2016 

Inovio Pharmaceuticals Inc: Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial . Center phase I trial to evaluate inovio's Zika dna vaccine . Says expect to complete subject dosing and report interim phase I results later this year .Health Canada's Health Products and Food Branch has also approved co's Zika study.  Full Article

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS